Viatris Inc.
VTRS Healthcare Drug Manufacturers Specialty & Generic
Viatris Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14.3 billion, down 2.98% from fiscal 2024. In the quarter to June 2026, revenue grew 4.88%, EPS fell 2,464.1%, free cash flow grew 101.1% and total debt fell 18.1%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for five consecutive years.
Follow VTRS
Viatris Inc. (VTRS) Total debt
Viatris Inc.'s total debt at the end of fiscal 2025 was $16.4B, unchanged from fiscal 2024. At the end of the quarter to 30 June 2026 it was $13.4B. Over the past ten years it has ranged from $7.4B (fiscal 2015) to $28.3B (fiscal 2020); the current reading is higher than 55% of that period. Viatris Inc. ranks 3rd of 86 Drug Manufacturers Specialty & Generic companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2025 | $16.4B | 2.77% |
| FY2024 | $16.0B | (11.83%) |
| FY2023 | $18.1B | (5.93%) |
| FY2022 | $19.3B | (16.52%) |
| FY2021 | $23.1B | (18.48%) |
| FY2020 | $28.3B | 106.98% |
| FY2019 | $13.7B | (1.30%) |
| FY2018 | $13.9B | (13.12%) |
| FY2017 | $16.0B | (5.57%) |
| FY2016 | $16.9B | 129.16% |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Jun 2026 | $13.4B | (6.92%) |
| Mar 2026 | $14.3B | (0.48%) |
| Dec 2025 | $14.4B | (11.37%) |
| Sep 2025 | $16.3B | (0.28%) |
| 42 more quarters | Free account |
Against its own ten years
Total debt against peers
| Company | Total debt |
|---|---|
| TAK Takeda Pharmaceutical Co. compare | $31.1B |
| TEVA Teva Pharmaceutical Industries Ltd. compare | $16.6B |
| VTRS Viatris Inc. | $13.4B |
| HLN Haleon PLC Sponsored ADR compare | $11.1B |
| ZTS Zoetis Inc. compare | $9.0B |
| ELAN Elanco Animal Health Incorporated compare | $3.9B |
| RDY Dr. Reddy's Laboratories Ltd compare | $760.0M |
| NBIX Neurocrine Biosciences, Inc. compare | $274.0M |
| UTHR United Therapeutics Corporation compare | $200.0M |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on VTRS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement